Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
Since 1986, MAPS has disbursed over $26 million to scientific research and public education about the risks and benefits of psychedelics and marijuana. This April, we're asking you to join us in celebrating our 30 years of pioneering research and honest education through the Global Psychedelic Dinners and 30th Anniversary Banquet and Celebration in Oakland, Calif. Almost all our support comes from individuals and family foundations.
MAPS has completed an international series of Phase 2 clinical trials of MDMA-assisted psychotherapy for PTSD, and is now preparing for the much larger Phase 3 trials required to obtain U.S. Food and Drug Administration (FDA) approval, starting in 2017. As long as we receive the necessary funding, we anticipate FDA approval for MDMA-assisted psychotherapy for PTSD as soon as 2021.
For more information, visit: http://www.maps.org/